4 reports of this reaction
1.7% of all NYSTATIN AND TRIAMCINOLONE ACETONIDE reports
#10 most reported adverse reaction
APPLICATION SITE PRURITUS is the #10 most commonly reported adverse reaction for NYSTATIN AND TRIAMCINOLONE ACETONIDE, manufactured by Alembic Pharmaceuticals Inc.. There are 4 FDA adverse event reports linking NYSTATIN AND TRIAMCINOLONE ACETONIDE to APPLICATION SITE PRURITUS. This represents approximately 1.7% of all 237 adverse event reports for this drug.
Patients taking NYSTATIN AND TRIAMCINOLONE ACETONIDE who experience application site pruritus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE PRURITUS is a less commonly reported adverse event for NYSTATIN AND TRIAMCINOLONE ACETONIDE, but still significant enough to appear in the safety profile.
In addition to application site pruritus, the following adverse reactions have been reported for NYSTATIN AND TRIAMCINOLONE ACETONIDE:
The following drugs have also been linked to application site pruritus in FDA adverse event reports:
APPLICATION SITE PRURITUS has been reported as an adverse event in 4 FDA reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE PRURITUS accounts for approximately 1.7% of all adverse event reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE, making it a notable side effect.
If you experience application site pruritus while taking NYSTATIN AND TRIAMCINOLONE ACETONIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.